News

Juvenile Chronic Arthritis

By

In a 30-year-old woman with decreased range of motion in several joints, radiographs show bony fusion, profound osteopenia, erosions and advanced arthrosis.

For the first time, the European Medicines Agency's biosimilars program has recommended approval of a monoclonal antibody. It has given thumbs-up to an alternative formulation of infliximab to treat inflammatory conditions including RA, ankylosing spondylitis, and psoriatic arthritis.

With the FDA poised to issue guidance for mobile health app designers, this review includes several well-regarded apps for rheumatoid arthritis and mentions a few newcomers.

Rheumatoid arthritis patients taking a combination of etanercept (Enbrel) and methotrexate do better, but only slightly, than those on monotherapy with the tumor necrosis factor-α inhibitor, according to a Canadian multicenter clinical trial.

Last week the major British journal published an exhaustive series of reviews on autoimmune rheumatic disease, summarized briefly here. Also new in the nonspecialty journals: Macitentan for pulmonary hypertension, small fiber neuropathy in Sjögren syndrome, and risk factors for infection with glucocorticoids.

Most fibromyalgia patients randomized to continuing milnacipran (Savella) at the end of a clinical trial never noticed an increase in pain. Patients in the placebo group had quite a different experience.

Contrary to American College of Rheumatology recommendations, analysis of data from a clinical trial reveals methotrexate monotherapy as the best initial treatment for early rheumatoid arthritis that has a poor outlook.

One reason no good solution yet exists for osteoarthritis may be that rheumatology has been viewing many disease processes as a single entity. In an editorial, four rheumatologists offer a new disease model that they hope will rationalize future clinical research.

This case and a bonus set of images from another woman with the same diagnosis reveal some of the many manifestations of her condition. Can you guess her diagnosis?

Evidence from animal and human studies supports efforts to use the natural lubricant proteoglycan 4 (lubricin) to protect joints threatened by injury or disease, primarily osteoarthritis. The only thing wanted now is clinical proof of the concept. Gregory Jay MD PhD reviews the history and the potential of this new strategy.

Progressive multifocal leukoencephalopathy (PML) is a rare but potentially fatal adverse effect of biologic therapy for rheumatologic disorders. Here, a specialist on the topic from Cleveland Clinic offers a brief review of the risks and realities.

New this week in the nonspecialty journals: Tattoos and sarcoidosis, oral ulcers and autoimmunity, gout and heart disease, and a review about a gene that affects autoimmune inflammation.

Patients with knee or shoulder pain often take it for granted that their damaged joint needs fixing, says this author. Preventing unnecessary surgery may begin with doctors who recognize and correct this misconception.